Russia grants India the right to manufacture "Sputnik" vaccine
Russia agreed today, Friday, to grant India the right to manufacture the "Sputnik V" anti-Corona vaccine, which it succeeded in reaching.
The Russian sovereign wealth fund and the Indian company Hetero for pharmaceutical products have agreed to produce more than 100 million doses of the "Sputnik V" vaccine against Covid-19 in India, according to the "Russia Today" website.
According to the statement, Hetero and the Russian Direct Investment Fund, which supports the vaccine and markets it globally, intend to start production of "Sputnik V" in India at the beginning of 2021.
The statement also mentioned that clinical trials of the vaccine in the second and third stages are still ongoing. The vaccine will also be produced in other countries, notably Brazil, China and South Korea.
While the head of the Russian sovereign fund Kirill Dmitriev said, "Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide an effective solution for the citizens of India in this difficult stage of the epidemic." Pointing out that he received "requests" of more than 1.2 billion doses of the "Sputnik" vaccine in "more than 50 countries."
The sovereign fund also clarified that "the price of one dose of" Sputnik V "for the international market will be less than 10 dollars" for a single dose, indicating that the vaccine for Russian citizens will be free.
The "Sputnik V" vaccine is currently in the third phase of clinical trials that are conducted according to an experimental approach in which neither the patient nor the doctor knows whether the given vaccine is real or fake, and the trials include 40,000 volunteers.
